Abstract
The aim of this article is to report a case of Aspergillus chorioretinitis successfully treated with intravitreal voriconazole based on an interventional case report. An immunodeficient patient, 34 years old, receiving systemic antifungal treatment for 1 month for invasive aspergillosis with necrotizing pneumonia and brain metastasis, who presented with blurred vision in his left eye. Visual acuity (VA) was 20/20 in his right eye, and 8/20 in his left eye. Ophthalmological examination showed a paramacular nodular yellowish chorioretinal lesion with intraretinal hemorrhages, in the absence of vitritis or anterior uveitis. The patient was treated with one dose of intravitreal voriconazole (100 μg/0.1 ml). One week after the intravitreal injection, the patient’s VA was 10/20, the retinal lesions had diminished, and the hemorrhages had disappeared. At 3-month follow-up, his AV was 20/20 with a residual retinal scar. The significant and rapid improvement in this patient suggests that early injection of intravitreal voriconazole may be the first therapeutic option in Aspergillus chorioretinitis, obviating the need for vitrectomy.
This is a preview of subscription content, log in via an institution to check access.
References
Moorthy R, Davis J, Yen Lowder C et al (2009) Inflamación intraocular y uveitis. In: Liesegang T, Skuta G, Cantor L (eds) Curso de Ciencias Básicas y Clínicas. Elsevier Science, Spain, pp 250–251
Sen P, Gopal L, Ranjan P (2006) Intravitreal voriconazole for drug-resistant fungal endophthalmitis. Retina 26:935–939
Groll A, Tragiannidis A (2010) Update on antifungal agents for paediatric patients. Clin Microbiol Infect 16:1343–1353. doi:10.1111/j.1469-0691.2010.03334.x
Herbrecht R (2004) Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti-infect Ther 2:485–497
Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415
Pfaller MA (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032–1037
Hariprasad SM, Mieler WF, Holz ER et al (2004) Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 122:42–47
Kramer M, Kramer MR, Blau H et al (2006) Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 113:1184–1186
Lin RC, Sanduja N, Hariprasad SM (2008) Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 24:245–248
Thiel M, Zinkernagel AS, Burhenne J et al (2007) Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 51:239–244
Hua G, Pennesi M, Shah K et al (2003) Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 101:183–189
Scott IU, Cruz-Villegas V, Flynn HW et al (2004) Delayed onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 137:583–585
Bagnoud M, Baglivo E, Hengstlerl J et al (2001) Endogenous fungal endophthalmitis: results of antifungal treatment with and without vitrectomy. Klin Monbl Augenheilkd 218:398–400
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vila Arteaga, J., Suriano, M.M. & Stirbu, O. Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis. Int Ophthalmol 31, 341–344 (2011). https://doi.org/10.1007/s10792-011-9455-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-011-9455-7